| Today’s Big NewsApr 17, 2024 |
| By Max Bayer Pfizer's 2023 cost-cutting wave swept up a specific R&D team that worked closely with academics to swiftly develop new medicines. A company spokesperson confirmed that Pfizer has closed labs associated with the Centers for Therapeutic Innovation. |
|
|
|
By Nick Paul Taylor GlobalData has put out a forecast that shows how GLP-1 drugs could rapidly redefine what big looks like in drug sales. The analysts expect Mounjaro to bring in as much in 2029 as Eli Lilly’s entire portfolio did in 2023—and are tipping its Alzheimer’s disease prospect donanemab to add a further $5 billion. |
By Angus Liu One-year data continued to support a more convenient, injectable version of Roche’s blockbuster multiple sclerosis drug Ocrevus ahead of an FDA decision, the Swiss pharma said. |
By Conor Hale Abbott’s medical device division’s sales grew by 14.2%, powered by double-digit growth across electrophysiology, neuromodulation and structural heart. |
|
Monday, April 22, 2024 | 10am ET / 7am PT Explore cutting-edge NASH research with a novel NAFLD/NASH animal model mirroring patient experiences. Witness Resmetirom's impact on fat accumulation using human cell-based in vitro models. Expect clinical relevance, quick insights in 12-16 weeks, and cost savings. Register now!
|
|
By Nick Paul Taylor Sage Therapeutics has set a bad PRECEDENT for dalzanemdor. The therapy failed to improve cognitive ability in a phase 2 Parkinson’s disease study, setting Sage off on the wrong foot at the start of a sequence of readouts that will define the future of the molecule. |
By Kevin Dunleavy In addition to their acclaimed efficacy against diabetes and obesity, GLP-1 drugs are gaining traction for their potential to treat a variety of other common disorders. Now, two trials have shown that Eli Lilly’s weight loss product Zepbound (tirzepatide) can help patients overcome obstructive sleep apnea (OSA). |
By Andrea Park The drug has shown promise in reducing triglycerides and the protein APOC3, meaning it could be used to treat many forms of dyslipidemia, a family of diseases in which lipids or lipoproteins are found in abnormally high or low amounts in the blood. |
By Fraiser Kansteiner Riding high on Teva’s success under its recent “Pivot to Growth” strategy, chief executive Richard Francis—in his first year at the helm of the generics and innovative medicines hybrid—has emerged as one of the industry’s top-paid CEOs for 2023. |
By Annalee Armstrong Fervent FDA watchers may note that the FDA typically warms to subsequent drugs in a class as they come in for review. But the Alzheimer’s space has never been like any other therapeutic area, so why would the regulatory process be any different? |
By Gabrielle Masson Sanofi’s global collaboration with IGM Biosciences has shrunk by half. The companies will now focus only on developing three IgM agonist antibodies for immunology and inflammation and shed three related oncology targets. |
By Conor Hale The company’s all-digital cell morphology analysis platform employs high-resolution microscopic imaging of samples taken during bone marrow aspiration procedures and automatically highlights different hematopoietic cell types in stained blood smears. |
By Andrea Park As COVID-19 moves into an endemic phase, though rates of coronavirus infections and hospitalizations continue to fall, cases of long COVID appear to be slowly ticking upward. |
By Zoey Becker The CDMO is reworking its small-scale business unit, which includes four global facilities, after a lack of investment in early-stage cell and gene therapy research projects. |
Fierce podcastsDon’t miss an episode |
| | Morgan Health has been investing in multiple businesses over the past three years that have the potential to improve employer-sponsored healthcare. This week on “Podnosis,” Paige Minemyer from Fierce Healthcare interviews Morgan Health Partner Dan Hartman about the company's investment strategy and how to make a memorable pitch. |
|
|---|
|
|
|
Monday, April 29, 2024 | 12:30pm ET / 9:30am PTLearn how evolving healthcare delivery impacts product positioning for Integrated Delivery Networks. Discover key messages, stakeholders, and shifts in IDN perceptions post-COVID-19. Claim your spot.
|
|
| WhitepaperAntibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your FREE white paper today! Sponsored by: Sengenics Corporation LLC |
| WhitepaperThe use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
| eBookUnlock the future of monoclonal antibody (mAb) manufacturing with a complete guide to enhancing productivity and quality for exceptional outcomes. Sponsored by: Thermo Fisher Scientific |
| WhitepaperThis paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperChoosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future. Sponsored by: PPD®️ Laboratory Services |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
